City Therapeutics has announced its launch accompanied by a $135m Series A financing to lead advancements in RNAi-based ...

Ipsen has received the UK MHRA's approval for its Elafibranor (Iqirvo) for the treatment of primary biliary cholangitis (PBC) ...

The manufacturing shift to meet growing cell and gene therapy demand, applying lessons from the Covid-19 pandemic to address ...

The companies will collaborate to hold a global Phase I combination trial of YL201 and Amgen’s Imdelltra for small cell lung ...

Less frequent dosing could provide Eli Lilly’s Ebglyss room to rival Sanofi and Regeneron’s blockbuster Dupixent.

Bayer has entered a collaboration with MOMA Therapeutics in which the two companies will advance a small molecule oncology ...

The Phase III trials will evaluate survodutide in metabolic dysfunction-associated steatohepatitis (MASH), fibrosis and ...

The MHRA’s 2024/25 business plan focuses on improving service delivery for its customers, enabling access to new technologies ...

ViiV Healthcare has announced plans to triple annual supply of long-acting cabotegravir for HIV PrEP to at least two million ...

Innovent Biologics and ASK Pharm have signed a strategic partnership for the commercialisation of limertinib for the ...

NP001 is designed to tackle the neurodegenerative disease through an immunologic mechanism as opposed to a neurologic one.

The safety review was requested by the French medicines agency, citing new safety reports that alter the risk profile of ...